GlassScriptPhysician profile
David Kenneth Best
NPI 1871583195
$16,347.09
in general payments reported to CMS, 2019-2025
19 companies · $14.19 in 2025
The $14.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,782 · 2021: $151 · 2022: $541 · 2023: $306 · 2024: $207 · 2025: $14.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $15,000.38 | 2019-2024 | Sublocade |
| Abbvie INC. | $340.49 | 2021-2024 | Ubrelvy |
| Alkermes, INC. | $141.02 | 2020-2023 | Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $134.17 | 2019 | |
| Glaxosmithkline, LLC. | $122.27 | 2023 | |
| Braeburn INC. | $97.52 | 2023-2024 | Brixadi |
| Pear Therapeutics (US), INC. | $92.87 | 2021-2022 | |
| Gilead Sciences, INC. | $61.70 | 2019-2022 | |
| Eisai INC. | $58.84 | 2022 | |
| Orexo US, INC. | $56.35 | 2019-2024 | Zubsolv |
| Novo Nordisk INC | $55.89 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.60 | 2022 | |
| Collegium Pharmaceutical, INC. | $33.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.90 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.56 | 2024 | Breztri |
| Ironshore Pharmaceuticals INC. | $17.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2022 | |
| Boston Scientific Corporation | $14.19 | 2025 | Varithena Administration Pack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.